Equity Compensation Plan - Summary of non-vested stock option activity (Detail) - $ / shares |
12 Months Ended | |||
|---|---|---|---|---|
Sep. 16, 2025 |
Sep. 16, 2024 |
Nov. 06, 2023 |
Dec. 31, 2024 |
|
| Share-Based Payment Arrangement [Abstract] | ||||
| Beginning , Option Shares | 0 | |||
| Granted , Option Shares | 10,000 | 10,000 | ||
| Ending , Option Shares | 10,000 | |||
| Exercisable , Option Shares | 0 | |||
| Beginning , Weighted-Average Exercise Price | $ 0 | |||
| Granted , Weighted-Average Exercise Price | $ 10.76 | $ 17.4 | $ 637.5 | 17.4 |
| Ending , Weighted-Average Exercise Price | 17.4 | |||
| Exercisable , Weighted-Average Exercise Price | $ 0 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. No definition available.
|